Trametinib

Generic Name
Trametinib
Brand Names
Mekinist, Spexotras
Drug Type
Small Molecule
Chemical Formula
C26H23FIN5O4
CAS Number
871700-17-3
Unique Ingredient Identifier
33E86K87QN
Background

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...

Indication

Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

It is used in combination with dabrafenib for the:
...

Associated Conditions
Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
Associated Therapies
-
Clinical Trials
Related News

A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors

First Posted Date
2021-05-19
Last Posted Date
2024-12-20
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Target Recruit Count
173
Registration Number
NCT04892017
Locations
🇺🇸

Siteman Cancer Center, Saint Louis, Missouri, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Rutgers Cancer Institute, New Brunswick, New Jersey, United States

and more 6 locations

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

First Posted Date
2021-03-17
Last Posted Date
2023-05-10
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Target Recruit Count
3
Registration Number
NCT04801966
Locations
🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

First Posted Date
2021-02-04
Last Posted Date
2024-03-25
Lead Sponsor
Saint Petersburg State University, Russia
Registration Number
NCT04739566
Locations
🇷🇺

Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies, Saint Petersburg, Russian Federation

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

First Posted Date
2020-12-19
Last Posted Date
2024-07-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT04675710
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Stanford School of Medicine, Stanford, California, United States

and more 3 locations

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Recruiting
Conditions
Melanoma
Interventions
Drug: dabrafenib
Drug: trametinib
First Posted Date
2020-12-14
Last Posted Date
2024-06-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
80
Registration Number
NCT04666272
Locations
🇨🇳

Novartis Investigative Site, Wuhan, China

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

First Posted Date
2020-09-28
Last Posted Date
2023-08-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2
Registration Number
NCT04566133
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

First Posted Date
2020-09-10
Last Posted Date
2024-11-11
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT04544202

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

First Posted Date
2020-09-10
Last Posted Date
2024-11-13
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
19
Registration Number
NCT04544111
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States

and more 4 locations

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Conditions
Melanoma
First Posted Date
2020-07-28
Last Posted Date
2024-02-08
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT04489433

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

First Posted Date
2020-07-27
Last Posted Date
2023-03-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
21
Registration Number
NCT04487106
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy